Skip to main content
Weiter zur Homepage der Europäischen Kommission (öffnet in neuem Fenster)
Deutsch de
CORDIS - Forschungsergebnisse der EU
CORDIS

Multispecific theranostic nano-engager platform

Ziel

"This ERC Proof of Concept proposal develops ""Nano-BITE,"" a multifunctional nanoparticle platform addressing limitations of current cancer immunotherapy. Existing bispecific antibodies like blinatumomab suffer from rapid kidney clearance due to small molecular size, requiring continuous intravenous infusion for weeks and showing poor efficacy in solid tumors. The Nano-BITE platform uses PLGA nanoparticles as scaffolds incorporating four integrated features: modular E3/K3 peptide chemistry enabling rapid attachment of nanobodies targeting NK cells and tumor antigens, extended circulation achieving greater than 24-hour half-life versus 7 hours for conventional engagers, localized IL-15 delivery for sustained NK cell activation within tumors without systemic toxicity, and integrated radioisotope chelators enabling PET imaging to track drug distribution and predict response. The platform's innovative ""plug-and-play"" design allows rapid adaptation to different cancers by swapping targeting modules within hours rather than 18-24 months required for new drug development. When imaging reveals antigen switching, subsequent doses can target different antigens using the same nanoparticle backbone. The 18-month validation plan includes optimizing formulation and demonstrating superior NK cell activation in vitro, followed by proving therapeutic efficacy in humanized mouse models of HER2-positive breast cancer. This approach could transform cancer immunotherapy from static treatments to dynamic platforms adapting to disease evolution, potentially capturing markets exceeding fifty billion dollars versus one to five billion for individual bispecifics."

Wissenschaftliches Gebiet (EuroSciVoc)

Programm/Programme

Thema/Themen

Finanzierungsplan

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Alle im Rahmen dieses Finanzierungsinstruments finanzierten Projekte anzeigen

Aufforderung zur Vorschlagseinreichung

(öffnet in neuem Fenster) ERC-2026-POC

Alle im Rahmen dieser Aufforderung zur Einreichung von Vorschlägen finanzierten Projekte anzeigen

Gastgebende Einrichtung

INSTITUT GUSTAVE ROUSSY
Netto-EU-Beitrag
€ 150 000,00
Adresse
Rue Camille Desmoulins 39
94805 Villejuif
Frankreich
Region
Ile-de-France Ile-de-France Val-de-Marne
Aktivitätstyp
Research Organisations
Links
Gesamtkosten
Keine Daten

Begünstigte (1)